Should These Companies’ Insider Selling Alarm Investors?

Numerous studies conclude that corporate insiders act as contrarian investors, as they usually tend to buy low and sell high. The efficient market hypothesis stipulates that all public information is fully reflected in a security’s market price, which practically means that insiders are not able to generate higher trading profits than non-insiders. However, this theory is not entirely true in real life, especially when it comes to insider buying. Of course, that does not mean that corporate insiders are trading on material non-public information, which is restricted by law, but these individuals do have a better understanding about their companies’ businesses and industries than most non-insiders. This in turn enables them to make very profitable trades, while non-insiders could capitalize on insiders’ “abnormal” trading skills by mimicking their trades (or at least examining these trades). For that reason, the following article will digest the recent insider selling activity registered at three U.S.-listed companies.

Prior to discussing the insider trading activity, let’s make you familiar with what Insider Monkey does. At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. But why do we track hedge fund activity? From one point of view we can argue that hedge funds are consistently underperforming when it comes to net returns over the last three years, when compared to the S&P 500. But that doesn’t mean that we should completely neglect their activity. There are various reasons behind the low hedge fund returns. Our research indicated that hedge funds’ long positions actually beat the market. In our back-tests covering the 1999-2012 period, hedge funds’ top small-cap stocks beat the S&P 500 index by double digits annually (read the details here).

UnitedHealth Group Inc. (NYSE:UNH) was among the companies that witnessed insider selling this past week. Non-Executive Chairman Richard T. Burke reported selling 50,000 shares on Thursday at prices in the range of $113.55 to $113.85 per share, trimming his total stake to 2.03 million shares. The Chairman also holds an indirect ownership stake of 86,000 shares, which are held by an irrevocable trust for the benefit of his children. Richard T. Burke is the founder of UnitedHealth Group and served as Chief Executive Officer of the company from 1977 to 1987, which makes it hard to believe that there is anyone else who knows more about this company than him. The diversified health and well-being company provides health care coverage and benefits services through the UnitedHealthcare business, and pharmacy care services and IT-enabled services through the Optum business. The shares of the company have advanced nearly 5% over the past 12-month period, and are up by 163% over the past five years. Healthcare spending in the United States accounts for 18% of the nation’s economy and has increased steadily over the past years, which partly explains UnitedHealth Group Inc. (NYSE:UNH)’s phenomenal stock performance. The company generated total revenues of $157.1 billion for 2015, as compared to $130.5 billion for 2014. Clearly, the company has been doing great in recent years, but does the Chairman’s sale represent a cause for concern? Credit Suisse’s analysts do not believe so, considering UnitedHealth Group among the best health care stock ideas for 2016. The investment bank has a price target of $133 on the stock, which yields an upside of at least 19%. Moreover, UnitedHealth Group seems to be undervalued relative to the overall health care industry, as the stock trades at a forward price-to-earnings ratio of 12.73 (the forward P/E ratio for the healthcare sector stands at 14.7). Boykin Curry’s Eagle Capital Management holds a 7.59 million-share position in UnitedHealth Group Inc. (NYSE:UNH) as of the end of the third quarter.

Follow Unitedhealth Group Inc (NYSE:UNH)

Let’s move on to the next page of this article, where we discuss the insider selling witnessed at Corning Incorporated (NYSE:GLW) and Align Technology Inc. (NASDAQ:ALGN).

Corning Incorporated (NYSE:GLW) also had one of its executives sell a sizable block of shares last week. Vice Chairman James B. Flaws sold 69,519 shares on Thursday at $18.5 apiece and currently owns 275,074 shares. He also served as the Chief Financial Officer of Corning from December 1997 to August 2015. The shares of the high-tech glass maker are down 24% over the past year, but are trading in positive territory thus far in 2016. The company did not have a great 2015 in terms of top- and bottom-line growth last year, but its management anticipates that business conditions will improve gradually in 2016. Corning generated core earnings per share of $1.40 on core sales of $9.8 billion in 2015, as compared to core EPS of $1.42 on $10 billion in core sales reported for 2014. Corning is widely-known for its Gorilla Glass, which is a scratch-resistant glass used in smartphones, but most of its revenues are generated from the sale of glass used in LCDs. The aggregate LCD glass price has been on a decline in the past several years, and yet the price decline in 2015 was the lowest in five years. Furthermore, the company anticipates that the moderation of LCD glass price declines will continue throughout 2016, which could assist the company in achieving a turnaround. Meanwhile, the stock trades at a forward P/E multiple of 11.35, which compares to the average of 15.87 for the S&P 500 Index. A total of 38 hedge funds tracked by Insider Monkey were invested in the company at the end of the third quarter, amassing 4.60% of its total shares. Kerr Neilson’s Platinum Asset Management owns 9.62 million shares of Corning Incorporated (NYSE:GLW) as of September 30.

Follow Corning Inc (NYSE:GLW)

The insider selling activity at Align Technology Inc. (NASDAQ:ALGN) has been intensifying over the past several months, so let’s try to figure out what might have propelled insiders’ bearishness. Director Gregory J. Santora unloaded 9,000 shares on Thursday at a weighted average price of $67.28, all of which were held by a family trust fund. All shares that were previously shown as owned directly by the Director are currently owned by the family trust, which now holds an ownership stake of 26,900 shares. The medical device company operates through two main segments: Clear Aligner, known as the Invisalign System; and Scanner and Services, which comprise the iTero intraoral scanners and OrthoCAD services. The company’s financial performance is highly dependent on the Clear Aligner segment, as it accounted for nearly 95% of net revenues for 2015. Invisalign is a very efficient approach to straightening teeth by utilizing a custom-made series of aligners (which are changed approximately every two weeks), and Align Technology aims at establishing Invisalign clear aligners as the main method for treating malocclusion. For that reason, the company started a new product policy called “Additional Aligners at No Charge” in July 2015. Align Technology reported revenues of $845.5 million for 2015, up by 11.0% on the year. In the meantime, the shares of the medical device company have advanced almost 20% over the past one-year period and are currently trading near an all-time high, so it is no wander why the company  has been witnessing escalating insider selling. Jacob Gottlieb’s Visium Asset Management was the owner of 1.37 million shares of Align Technology Inc. (NASDAQ:ALGN) at the end of September.

Follow Align Technology Inc (NASDAQ:ALGN)

Disclosure: None